Cargando…
An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites
The spread of multidrug-resistant bacteria, such as the skin commensal Staphylococcus aureus, is a worldwide health challenge; new methods to counteract opportunistic pathogen growth and virulence are urgent. We compared the activity of Lacticaseibacillus rhamnosus LR06 (DSM 21981) and Lactobacillus...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126979/ https://www.ncbi.nlm.nih.gov/pubmed/35606510 http://dx.doi.org/10.1038/s41598-022-12718-z |
_version_ | 1784712248885772288 |
---|---|
author | Squarzanti, Diletta Francesca Zanetta, Paola Ormelli, Margherita Manfredi, Marcello Barberis, Elettra Vanella, Virginia Vita Amoruso, Angela Pane, Marco Azzimonti, Barbara |
author_facet | Squarzanti, Diletta Francesca Zanetta, Paola Ormelli, Margherita Manfredi, Marcello Barberis, Elettra Vanella, Virginia Vita Amoruso, Angela Pane, Marco Azzimonti, Barbara |
author_sort | Squarzanti, Diletta Francesca |
collection | PubMed |
description | The spread of multidrug-resistant bacteria, such as the skin commensal Staphylococcus aureus, is a worldwide health challenge; new methods to counteract opportunistic pathogen growth and virulence are urgent. We compared the activity of Lacticaseibacillus rhamnosus LR06 (DSM 21981) and Lactobacillus johnsonii LJO02 (DSM 33828) cell-free supernatants (CFSs) produced in the conventional animal derivative-based MRS medium and an innovative animal derivative-free broth (TIL) versus the MDR S. aureus (ATCC 43300). CFS influence was assessed towards the viability, metabolic activity, and ability to form biofilm of the MDR strain through optical density, alamarBlue assay, and crystal violet staining; their content in short-chain fatty acids, lactic acid, and proteins was analysed via high-resolution mass spectrometry and gas chromatography. All CFSs reduce viable and metabolically active S. aureus, being TIL more efficient compared to MRS in stimulating lactic acid bacteria metabolism and decreasing S. aureus biofilm formation. Particularly, the CFS from LJO02 grown in TIL has the best efficacy, revealing a high amount of lactic acid and 59 peculiar proteins; its effectiveness is partially maintained upon trypsin and proteinase K treatments, but not by pepsin and pH basification. Therefore, antagonistic CFSs may represent a strategic prevention approach, with bacteriotherapeutic and bio-repair potential. |
format | Online Article Text |
id | pubmed-9126979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91269792022-05-25 An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites Squarzanti, Diletta Francesca Zanetta, Paola Ormelli, Margherita Manfredi, Marcello Barberis, Elettra Vanella, Virginia Vita Amoruso, Angela Pane, Marco Azzimonti, Barbara Sci Rep Article The spread of multidrug-resistant bacteria, such as the skin commensal Staphylococcus aureus, is a worldwide health challenge; new methods to counteract opportunistic pathogen growth and virulence are urgent. We compared the activity of Lacticaseibacillus rhamnosus LR06 (DSM 21981) and Lactobacillus johnsonii LJO02 (DSM 33828) cell-free supernatants (CFSs) produced in the conventional animal derivative-based MRS medium and an innovative animal derivative-free broth (TIL) versus the MDR S. aureus (ATCC 43300). CFS influence was assessed towards the viability, metabolic activity, and ability to form biofilm of the MDR strain through optical density, alamarBlue assay, and crystal violet staining; their content in short-chain fatty acids, lactic acid, and proteins was analysed via high-resolution mass spectrometry and gas chromatography. All CFSs reduce viable and metabolically active S. aureus, being TIL more efficient compared to MRS in stimulating lactic acid bacteria metabolism and decreasing S. aureus biofilm formation. Particularly, the CFS from LJO02 grown in TIL has the best efficacy, revealing a high amount of lactic acid and 59 peculiar proteins; its effectiveness is partially maintained upon trypsin and proteinase K treatments, but not by pepsin and pH basification. Therefore, antagonistic CFSs may represent a strategic prevention approach, with bacteriotherapeutic and bio-repair potential. Nature Publishing Group UK 2022-05-23 /pmc/articles/PMC9126979/ /pubmed/35606510 http://dx.doi.org/10.1038/s41598-022-12718-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Squarzanti, Diletta Francesca Zanetta, Paola Ormelli, Margherita Manfredi, Marcello Barberis, Elettra Vanella, Virginia Vita Amoruso, Angela Pane, Marco Azzimonti, Barbara An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title | An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title_full | An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title_fullStr | An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title_full_unstemmed | An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title_short | An animal derivative-free medium enhances Lactobacillus johnsonii LJO02 supernatant selective efficacy against the methicillin (oxacillin)-resistant Staphylococcus aureus virulence through key-metabolites |
title_sort | animal derivative-free medium enhances lactobacillus johnsonii ljo02 supernatant selective efficacy against the methicillin (oxacillin)-resistant staphylococcus aureus virulence through key-metabolites |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126979/ https://www.ncbi.nlm.nih.gov/pubmed/35606510 http://dx.doi.org/10.1038/s41598-022-12718-z |
work_keys_str_mv | AT squarzantidilettafrancesca ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT zanettapaola ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT ormellimargherita ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT manfredimarcello ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT barberiselettra ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT vanellavirginiavita ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT amorusoangela ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT panemarco ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT azzimontibarbara ananimalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT squarzantidilettafrancesca animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT zanettapaola animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT ormellimargherita animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT manfredimarcello animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT barberiselettra animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT vanellavirginiavita animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT amorusoangela animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT panemarco animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites AT azzimontibarbara animalderivativefreemediumenhanceslactobacillusjohnsoniiljo02supernatantselectiveefficacyagainstthemethicillinoxacillinresistantstaphylococcusaureusvirulencethroughkeymetabolites |